Risk factors for sinusoidal obstruction syndrome by univariate analysis
| . | SOS . | P . | Odds ratio (95% CI) . | |
|---|---|---|---|---|
| Yes n=88 . | No n=339 . | |||
| Male:female | 49:39 | 206:133 | .38 | 0.81 (0.50-1.30) |
| Median age, y (range) | 34.5 (6-33) | 30 (0-66) | .62 | NA |
| Underlying disease, no. (%) | ||||
| Lymphoma | 7 (8) | 135 (40) | < .001 | 0.13 (0.06-0.30) |
| Acute leukemia/MDS | 41 (46) | 88 (26) | < .001 | 2.49 (1.49-4.15) |
| Chronic myeloid leukemia | 26 (29) | 29 (8) | < .001 | 4.48 (2.37-8.48) |
| Multiple myeloma | 1 (1) | 52 (15) | < .001 | 0.06 (0.02-0.43) |
| Neoplastic disease, no. (%) | 79 (90) | 316 (93) | .27 | 0.64 (0.28-1.43) |
| Advanced underlying disease, no. (%) | 53 (60) | 262 (77) | .001 | 0.44 (0.27-0.73) |
| Allogeneic HSC transplantation, no. (%) | 82 (93) | 164 (48) | < .001 | 14.60 (6.20-34.30) |
| Unrelated donor allogeneic HSC transplantation, no. (%) | 15/82 (18) | 46/164 (28) | .15 | 1.31 (0.69-2.47) |
| Matched-related donor allogeneic HSC transplantation, no. (%) | 79/82 (96) | 136/164 (83) | .003 | 5.42 (1.60-18.40) |
| History of hepatitis, no. (%) | 4 (4) | 3 (1) | .04 | 5.33 (1.17-24.30) |
| CMV-positive recipient, no. (%) | 78 (89) | 298 (88) | .85 | 1.07 (0.51-2.24) |
| Previous HSC transplantation, no. (%) | 5 (6) | 35 (10) | .18 | 0.52 (0.20-1.38) |
| Receipt of imatinib, no. (%) | 15 (17) | 14 (4) | < .001 | 4.77 (2.21-10.30) |
| Receipt of gemtuzumab, no. (%) | 1 (1) | 0 | .21 | NA |
| Receipt of vancomycin or acyclovir, no. (%) | 2 (2) | 7 (2) | .999 | 1.10 (0.22-5.40) |
| Busulfan-based conditioning regimen, no. (%) | 46 (52) | 73 (21) | < .001 | 3.99 (2.44-6.53) |
| TBI-based conditioning regimen, no. (%) | 23 (26) | 62 (18) | .10 | 1.58 (0.91-2.74) |
| Myeloablative HSC transplantation, no. (%) | 81 (92) | 308 (91) | .73 | 1.16 (0.49-2.74) |
| Bone marrow as the source of stem cells, no. (%) | 60 (68) | 108 (32) | < .001 | 4.58 (2.69-7.83) |
| Methotrexate in the prophylaxis for GVHD, no. (%) | 76/82 (93) | 142/164 (86) | .13 | 1.96 (0.76-5.05) |
| Hepatic dysfunction, no. (%) | 26 (29) | 94 (28) | .73 | 1.09 (0.65-1.83) |
| . | SOS . | P . | Odds ratio (95% CI) . | |
|---|---|---|---|---|
| Yes n=88 . | No n=339 . | |||
| Male:female | 49:39 | 206:133 | .38 | 0.81 (0.50-1.30) |
| Median age, y (range) | 34.5 (6-33) | 30 (0-66) | .62 | NA |
| Underlying disease, no. (%) | ||||
| Lymphoma | 7 (8) | 135 (40) | < .001 | 0.13 (0.06-0.30) |
| Acute leukemia/MDS | 41 (46) | 88 (26) | < .001 | 2.49 (1.49-4.15) |
| Chronic myeloid leukemia | 26 (29) | 29 (8) | < .001 | 4.48 (2.37-8.48) |
| Multiple myeloma | 1 (1) | 52 (15) | < .001 | 0.06 (0.02-0.43) |
| Neoplastic disease, no. (%) | 79 (90) | 316 (93) | .27 | 0.64 (0.28-1.43) |
| Advanced underlying disease, no. (%) | 53 (60) | 262 (77) | .001 | 0.44 (0.27-0.73) |
| Allogeneic HSC transplantation, no. (%) | 82 (93) | 164 (48) | < .001 | 14.60 (6.20-34.30) |
| Unrelated donor allogeneic HSC transplantation, no. (%) | 15/82 (18) | 46/164 (28) | .15 | 1.31 (0.69-2.47) |
| Matched-related donor allogeneic HSC transplantation, no. (%) | 79/82 (96) | 136/164 (83) | .003 | 5.42 (1.60-18.40) |
| History of hepatitis, no. (%) | 4 (4) | 3 (1) | .04 | 5.33 (1.17-24.30) |
| CMV-positive recipient, no. (%) | 78 (89) | 298 (88) | .85 | 1.07 (0.51-2.24) |
| Previous HSC transplantation, no. (%) | 5 (6) | 35 (10) | .18 | 0.52 (0.20-1.38) |
| Receipt of imatinib, no. (%) | 15 (17) | 14 (4) | < .001 | 4.77 (2.21-10.30) |
| Receipt of gemtuzumab, no. (%) | 1 (1) | 0 | .21 | NA |
| Receipt of vancomycin or acyclovir, no. (%) | 2 (2) | 7 (2) | .999 | 1.10 (0.22-5.40) |
| Busulfan-based conditioning regimen, no. (%) | 46 (52) | 73 (21) | < .001 | 3.99 (2.44-6.53) |
| TBI-based conditioning regimen, no. (%) | 23 (26) | 62 (18) | .10 | 1.58 (0.91-2.74) |
| Myeloablative HSC transplantation, no. (%) | 81 (92) | 308 (91) | .73 | 1.16 (0.49-2.74) |
| Bone marrow as the source of stem cells, no. (%) | 60 (68) | 108 (32) | < .001 | 4.58 (2.69-7.83) |
| Methotrexate in the prophylaxis for GVHD, no. (%) | 76/82 (93) | 142/164 (86) | .13 | 1.96 (0.76-5.05) |
| Hepatic dysfunction, no. (%) | 26 (29) | 94 (28) | .73 | 1.09 (0.65-1.83) |
SOS indicates sinusoidal obstruction syndrome; 95% CI, 95% confidence interval; NA, not applicable; MDS, myelodysplasia; HSC, hematopoietic stem cell; CMV, cytomegalovirus; TBI, total body irradiation; GVHD, graft-versus-host disease; and TPN, total parenteral nutrition.